ATE240139T1 - Co-kristallisationsprozess - Google Patents

Co-kristallisationsprozess

Info

Publication number
ATE240139T1
ATE240139T1 AT00910766T AT00910766T ATE240139T1 AT E240139 T1 ATE240139 T1 AT E240139T1 AT 00910766 T AT00910766 T AT 00910766T AT 00910766 T AT00910766 T AT 00910766T AT E240139 T1 ATE240139 T1 AT E240139T1
Authority
AT
Austria
Prior art keywords
crystals
crystallization
enantiomers
chiral
crystal
Prior art date
Application number
AT00910766T
Other languages
English (en)
Inventor
Karl Reuter
Original Assignee
Reuter Chemische Appbau Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reuter Chemische Appbau Kg filed Critical Reuter Chemische Appbau Kg
Application granted granted Critical
Publication of ATE240139T1 publication Critical patent/ATE240139T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
AT00910766T 1999-03-05 2000-03-03 Co-kristallisationsprozess ATE240139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200648A EP1034826A1 (de) 1999-03-05 1999-03-05 Co-Kristallisationsverfahren
PCT/EP2000/001858 WO2000053283A1 (en) 1999-03-05 2000-03-03 Co-crystallization process

Publications (1)

Publication Number Publication Date
ATE240139T1 true ATE240139T1 (de) 2003-05-15

Family

ID=8239950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910766T ATE240139T1 (de) 1999-03-05 2000-03-03 Co-kristallisationsprozess

Country Status (8)

Country Link
US (1) US6570036B1 (de)
EP (2) EP1034826A1 (de)
JP (1) JP4896294B2 (de)
AT (1) ATE240139T1 (de)
AU (1) AU3285800A (de)
DE (1) DE60002679T2 (de)
ES (1) ES2199144T3 (de)
WO (1) WO2000053283A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1161290E (pt) * 1999-03-17 2007-12-14 Reuter Chemische Appbau Kg Cristalização de emulsões com reciclagem
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US20040110957A1 (en) * 2002-12-05 2004-06-10 Honeywell International, Inc. Process for the synthesis of an antiviral compound
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
TWI335227B (en) 2004-02-25 2011-01-01 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
US20090246288A1 (en) * 2004-02-25 2009-10-01 Pharmaceutical Industry Technology And Development Center Taste-masking oral dosage form and method of preparing the same
US8601530B2 (en) * 2006-09-19 2013-12-03 The Invention Science Fund I, Llc Evaluation systems and methods for coordinating software agents
BRPI0916197B1 (pt) 2008-07-29 2018-01-23 Poxel Processo para isolar componentes enantioméricos de uma mistura de enantiômeros
EP2413911B1 (de) 2009-03-31 2014-02-19 KRKA, D.D., Novo Mesto Progressive emulsionskristallisation
US8716520B2 (en) 2010-01-15 2014-05-06 Lupin Limited Method of resolution of (RS)- 1,1′-BI-2-naphthol for obtaining enantiomeric pure I.E. (S)-(−)-1,1′-BI-2-naphthol and/or (R)-(+)-1,1′-BI-2-naphthol via co-crystal formation with optically active derivatives of γ-amino acids
EP2364977A1 (de) 2010-01-26 2011-09-14 Reuter Chemische Apparatebau KG Verfahren zur Enantiomerenanreicherung von 3-Methyl-1-(2-Piperidinphenyl)-1-Butylamin
CA2805341C (en) 2010-03-16 2018-06-12 Imperial Sugar Company Process for the manufacture of co-crystallized sucrose natural sweeteners and the products thereof
CN102633692B (zh) * 2012-04-11 2014-04-09 上海康福赛尔医药科技有限公司 一种光学活性左旋和右旋3-溴樟脑-8-磺酸的制备方法
CN102633690B (zh) * 2012-04-11 2014-04-09 上海康福赛尔医药科技有限公司 诱导结晶拆分外消旋樟脑磺酸制左旋和右旋樟脑磺酸方法
EP2671858A1 (de) 2012-06-08 2013-12-11 Université Catholique De Louvain Verfahren zur Racematspaltung von Etiracetam
WO2013186390A1 (en) 2012-06-15 2013-12-19 Farma Grs, D.O.O. Selective crystallization processes using reverse micelle and w/o microemulsion systems - multitask emulsion crystallization (mec)
JOP20190251A1 (ar) 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
CN113195494B (zh) 2018-12-04 2024-06-28 美蒂斯制药公司 包含非外消旋比例的R-2-（取代的磺酰基）-六氢-吡咯并[1,2-a]吡嗪-6（2H）-酮和S-2-（取代的磺酰基）-六氢-吡咯并[1,2- a]吡嗪-6（2H）-酮的协同组合物
BR112021010739A2 (pt) 2018-12-04 2021-08-24 Metys Pharmaceuticals AG Composições sinérgicas compreendendo (r)-(2-(2-oxopirrolidina-1-il)butanamida e (s)-2-(2-oxopirrolidina-1-il)butanamida) em uma proporção não racêmica
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
BR112021024125A2 (pt) 2019-06-24 2022-03-22 Philip Morris Products Sa Composições e métodos para controle de parasitas
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
EP4041399A1 (de) 2019-10-02 2022-08-17 Tolremo Therapeutics AG Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung zur behandlung oder linderung von krebs
EP4172156A1 (de) 2020-06-24 2023-05-03 Philip Morris Products S.A. Zusammensetzungen und verfahren zur bekämpfung von parasiten
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
WO2021260110A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
EP3939578A1 (de) 2020-07-13 2022-01-19 Novaremed Ltd. Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
EP3964497A1 (de) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
IL307402A (en) 2021-04-07 2023-12-01 Tolremo Therapeutics Ag The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865311A (en) * 1958-09-28 1961-04-12 Ajinomoto Kk Process for continuous resolution of racemic amino acids
JPS5655360A (en) * 1979-10-15 1981-05-15 Hiroyuki Nohira Optical resolution of (+-)-phenylglycine and/or (+-)-camphor-sulfonic acid
JPS5686138A (en) * 1979-12-18 1981-07-13 Hiroyuki Nohira Optical resolution of (+-)phenylglycine and (+-)camphorsulfonic acid
GB9126832D0 (en) * 1991-12-18 1992-02-19 Sandoz Ltd Separation process
EP0777651A1 (de) 1994-08-19 1997-06-11 Chiroscience Limited Verfahren zur trennung der enantiomeren eines bicyclischen lactams
ES2182025T3 (es) * 1996-03-10 2003-03-01 Reuter Chemischer Appbau Kg Procedimiento de separacion.
NL1004346C2 (nl) * 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.

Also Published As

Publication number Publication date
ES2199144T3 (es) 2004-02-16
WO2000053283A1 (en) 2000-09-14
JP2002538228A (ja) 2002-11-12
US6570036B1 (en) 2003-05-27
EP1156864A1 (de) 2001-11-28
DE60002679T2 (de) 2004-04-08
AU3285800A (en) 2000-09-28
EP1034826A1 (de) 2000-09-13
DE60002679D1 (de) 2003-06-18
JP4896294B2 (ja) 2012-03-14
EP1156864B1 (de) 2003-05-14

Similar Documents

Publication Publication Date Title
ATE240139T1 (de) Co-kristallisationsprozess
DE69133576D1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
IS2666B (is) Aðferð við ljósfræðilega hreinsun á bensimidasólafleiðum með hækkað hlutfall enantíómera
NO974779L (no) FremgangsmÕte for separasjon av en blanding av enantiomere
ES2149800T3 (es) Procedimientos enzimaticos para la resolucion de mezclas enantiomericas de compuestos utiles como intermediarios en la preparacion de taxanos.
PT1025067E (pt) Processo para a cristalizacao de compostos impedidos estereoquimicamente
ES8601100A1 (es) Un procedimiento para producir 3-(3, 4-dihidroxifenil) serina
IT8922075A0 (it) Processo per l'inversione stereochimica di (2s,3s)-2-ammino-3-fenil-1 ,3-propandioli nei corrispondenti enantiomeri (2r,3r)
ATE268166T1 (de) Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol
ATE288891T1 (de) Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
DE50209620D1 (de) Verfahren zur Herstellung von kristallinem Cholinascorbat
ATE387425T1 (de) Verfahren zur herstellung von bicalutamid
DK0749969T3 (da) Fremgangsmåde til fremstilling af polymorf form I af d4T
PT880525E (pt) Processo para a preparacao de galantamina
NO990159L (no) FremgangsmÕte for fremstilling av enantiomerisk anrikede N-acylazetidin-2-karboksylsyrer
PT1140794E (pt) Novo processo de preparacao de aminoacidos quirais
PT98726A (pt) Processo de transformacao do acido 2-(3-benzoilfenil)propionico-r(-) no isomeros(+)
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
FI875602A0 (fi) Optiskt aktivt tetrahydro-2-furanonderivat saosom miksobicid.
DK0924206T3 (da) Fremgangsmåde til fremstilling af (R)-3-hydroxy-4-butyrolacton anvendeligt til fremstilling af (R)-carnitin
GEP19991791B (en) Pharmacologically Active Enantiomers and Process for its Production
DE69819479D1 (de) Verfahren zur herstellung eines enantiomers von narwedin
DE50204211D1 (de) Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on- und 1,3-Oxathiolan-5-on-Derivaten
NO175251C (no) Fremgangsmåte for racematspalting av 2,2-dimetylcyklopropankarboksylsyre

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156864

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution